- Home
- PCM vs OKYO Comparison
PCM vs OKYO Comparison
Compare PCM & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | OKYO |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 78.2M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCM | OKYO |
|---|---|---|
| Price | $4.89 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 68.9K | 60.6K |
| Earning Date | 01-01-0001 | 07-20-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.83 | $1.26 |
| 52 Week High | $6.29 | $3.20 |
Technical Indicators
Market Signals| Indicator | PCM | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 42.80 |
| Support Level | $4.85 | N/A |
| Resistance Level | $5.83 | $1.70 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 5.00 | 40.12 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.